Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study

Gionata Spagnoletti; E Favi; A Gargiulo; Maria Paola Salerno; Franco Citterio

doi:10.1016/j.transproceed.2011.03.018

Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study

Gionata Spagnoletti, E Favi, A Gargiulo, Maria Paola Salerno, Franco Citterio

Università Cattolica del Sacro Cuore

Risultato della ricerca: Contributo in rivista › Articolo in rivista

6 Citazioni (Scopus)

Abstract

The half-life of everolimus is approximately 28 hours, but everolimus is generally administered twice a day. The aim of this prospective, single-center, exploratory study was to compare the efficacy and safety of a once a day everolimus (OD) with the standard twice a day administration regimen (BID) as immunosuppressive therapy in renal transplantation.

Lingua originale	English
pagine (da-a)	1010-1012
Numero di pagine	3
Rivista	Transplantation Proceedings
Volume	43
DOI	https://doi.org/10.1016/j.transproceed.2011.03.018
Stato di pubblicazione	Pubblicato - 2011

Keywords

Administration, Oral
Antibodies, Monoclonal
Calcineurin
Chi-Square Distribution
Drug Administration Schedule
Drug Monitoring
Drug Therapy, Combination
Female
Graft Rejection
Graft Survival
Humans
Immunosuppressive Agents
Italy
Kidney Transplantation
Male
Pilot Projects
Prospective Studies
Recombinant Fusion Proteins
Risk Assessment
Risk Factors
Sirolimus
Time Factors
Treatment Outcome

Accesso al documento

10.1016/j.transproceed.2011.03.018

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{39e5d7e73a714e66b04de80ff188171c,

title = "Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study",

abstract = "The half-life of everolimus is approximately 28 hours, but everolimus is generally administered twice a day. The aim of this prospective, single-center, exploratory study was to compare the efficacy and safety of a once a day everolimus (OD) with the standard twice a day administration regimen (BID) as immunosuppressive therapy in renal transplantation.",

keywords = "Administration, Oral, Antibodies, Monoclonal, Calcineurin, Chi-Square Distribution, Drug Administration Schedule, Drug Monitoring, Drug Therapy, Combination, Female, Graft Rejection, Graft Survival, Humans, Immunosuppressive Agents, Italy, Kidney Transplantation, Male, Pilot Projects, Prospective Studies, Recombinant Fusion Proteins, Risk Assessment, Risk Factors, Sirolimus, Time Factors, Treatment Outcome, Administration, Oral, Antibodies, Monoclonal, Calcineurin, Chi-Square Distribution, Drug Administration Schedule, Drug Monitoring, Drug Therapy, Combination, Female, Graft Rejection, Graft Survival, Humans, Immunosuppressive Agents, Italy, Kidney Transplantation, Male, Pilot Projects, Prospective Studies, Recombinant Fusion Proteins, Risk Assessment, Risk Factors, Sirolimus, Time Factors, Treatment Outcome",

author = "Gionata Spagnoletti and E Favi and A Gargiulo and Salerno, {Maria Paola} and Franco Citterio",

year = "2011",

doi = "10.1016/j.transproceed.2011.03.018",

language = "English",

volume = "43",

pages = "1010--1012",

journal = "Transplantation Proceedings",

issn = "0041-1345",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study

AU - Spagnoletti, Gionata

AU - Favi, E

AU - Gargiulo, A

AU - Salerno, Maria Paola

AU - Citterio, Franco

PY - 2011

Y1 - 2011

N2 - The half-life of everolimus is approximately 28 hours, but everolimus is generally administered twice a day. The aim of this prospective, single-center, exploratory study was to compare the efficacy and safety of a once a day everolimus (OD) with the standard twice a day administration regimen (BID) as immunosuppressive therapy in renal transplantation.

AB - The half-life of everolimus is approximately 28 hours, but everolimus is generally administered twice a day. The aim of this prospective, single-center, exploratory study was to compare the efficacy and safety of a once a day everolimus (OD) with the standard twice a day administration regimen (BID) as immunosuppressive therapy in renal transplantation.

KW - Administration, Oral

KW - Antibodies, Monoclonal

KW - Calcineurin

KW - Chi-Square Distribution

KW - Drug Administration Schedule

KW - Drug Monitoring

KW - Drug Therapy, Combination

KW - Female

KW - Graft Rejection

KW - Graft Survival

KW - Humans

KW - Immunosuppressive Agents

KW - Italy

KW - Kidney Transplantation

KW - Male

KW - Pilot Projects

KW - Prospective Studies

KW - Recombinant Fusion Proteins

KW - Risk Assessment

KW - Risk Factors

KW - Sirolimus

KW - Time Factors

KW - Treatment Outcome

KW - Administration, Oral

KW - Antibodies, Monoclonal

KW - Calcineurin

KW - Chi-Square Distribution

KW - Drug Administration Schedule

KW - Drug Monitoring

KW - Drug Therapy, Combination

KW - Female

KW - Graft Rejection

KW - Graft Survival

KW - Humans

KW - Immunosuppressive Agents

KW - Italy

KW - Kidney Transplantation

KW - Male

KW - Pilot Projects

KW - Prospective Studies

KW - Recombinant Fusion Proteins

KW - Risk Assessment

KW - Risk Factors

KW - Sirolimus

KW - Time Factors

KW - Treatment Outcome

UR - http://hdl.handle.net/10807/52178

U2 - 10.1016/j.transproceed.2011.03.018

DO - 10.1016/j.transproceed.2011.03.018

M3 - Article

SN - 0041-1345

VL - 43

SP - 1010

EP - 1012

JO - Transplantation Proceedings

JF - Transplantation Proceedings

ER -

Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo